The present invention relates to methods and pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome. In particular, the present invention relates to a method of treating left ventricular hypertrophy and dysfunction associated to metabolic syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one agent capable of raising the expression of IGFBP2.